DexCom, Inc. (NASDAQ:DXCM) Shares Bought by Bank of Nova Scotia

Bank of Nova Scotia raised its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 54.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 268,740 shares of the medical device company's stock after acquiring an additional 94,877 shares during the quarter. Bank of Nova Scotia owned 0.07% of DexCom worth $20,900,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Rathbones Group PLC grew its holdings in shares of DexCom by 2.1% in the 4th quarter. Rathbones Group PLC now owns 1,159,013 shares of the medical device company's stock worth $90,136,000 after acquiring an additional 24,314 shares during the period. Cerity Partners LLC boosted its position in DexCom by 11.4% during the fourth quarter. Cerity Partners LLC now owns 66,890 shares of the medical device company's stock worth $5,101,000 after purchasing an additional 6,840 shares in the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in DexCom in the fourth quarter valued at $699,000. Quadrant Capital Group LLC raised its stake in shares of DexCom by 9.9% during the 4th quarter. Quadrant Capital Group LLC now owns 3,213 shares of the medical device company's stock worth $250,000 after buying an additional 289 shares during the last quarter. Finally, Envestnet Asset Management Inc. raised its stake in shares of DexCom by 13.5% during the 4th quarter. Envestnet Asset Management Inc. now owns 584,065 shares of the medical device company's stock worth $45,423,000 after buying an additional 69,535 shares during the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on DXCM shares. Cfra Research upgraded shares of DexCom to a "hold" rating in a report on Friday, March 21st. Citigroup raised their price objective on shares of DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a research note on Tuesday, March 4th. Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Baird R W upgraded DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Finally, Mizuho began coverage on DexCom in a report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price target for the company. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $99.00.

DexCom Trading Up 1.4 %

DexCom stock traded up $0.91 during midday trading on Tuesday, reaching $68.30. The stock had a trading volume of 1,381,634 shares, compared to its average volume of 4,182,377. The stock's 50-day simple moving average is $76.49 and its 200 day simple moving average is $76.68. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $139.24. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The stock has a market capitalization of $26.78 billion, a PE ratio of 47.76, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Transactions at DexCom

In related news, CEO Kevin R. Sayer sold 33,359 shares of the company's stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the sale, the chief executive officer now directly owns 319,037 shares of the company's stock, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of the firm's stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the transaction, the chief operating officer now directly owns 268,644 shares in the company, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 105,009 shares of company stock valued at $8,044,178 over the last 90 days. Corporate insiders own 0.30% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.